Allogeneic BCMA-Targeting CAR-T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 Universal Trial Interim Results
Recommended
Allogeneic BCMA-Targeting CAR-T Cells in Relapsed/Refractory Multiple Myeloma: Phase 1 Universal Trial Interim Results
We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->